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Missense mutations and extra copies of the a-Synuclein gene result in Parkinson disease (PD). Human stem
and progenitor cells can be expanded from embryonic tissues and provide a source of non-transformed
neural cells to explore the effects of these pathogenic mutations specifically in human nervous tissue. We
over-expressed the wild type, A53T and A30P forms of a-synuclein in expanded populations of
progenitors derived from the human fetal cortex. The protein localized in the nucleus and around micro-
vesicles. Only the A53T form was acutely toxic, suggesting a unique vulnerability of these progenitors to
this mutation. Interestingly, constitutive over-expression of wild-type a-synuclein progressively impaired
the innate ability of progenitors to switch toward gliogenesis at later passages. To explore the effect of
a-synuclein on neuronal subtypes selectively affected in PD, such as dopaminergic neurons, a-synuclein
and its mutations were also over-expressed in terminally differentiating neuroectodermal cultures derived
from human embryonic stem cells (hESC). Alpha-synuclein induced acute cytotoxicity and reduced the
number of neurons expressing either tyrosine hydroxylase or gamma-aminobutyric acid over time.
Consistent with the selective vulnerability of ventral midbrain dopaminergic neurons, a-synuclein cyto-
toxicity appeared most pronounced following FGF8/SHH specification and was decreased by inhibition of
dopamine synthesis. Together, these data show that a-synuclein over-expressed in human neural embryonic
cells results in patterns of degeneration that in some cases match features of Parkinson Disease. Thus,
neural cells derived from hESC provide a useful model system to understand the development of
a-synuclein-related pathologies and allow therapeutic drug screening.
INTRODUCTION
Missense mutations (A53T, A30P and E46K) (1–3), dupli-
cation (4) and triplication (5) of the a-Synuclein gene
(PARK1 locus) have been found to cause autosomal dominant
Parkinson disease (PD). Thus, both increased a-Synuclein
gene dosage and mutations favoring its conversion to abnor-
mally folded species forming oligomers appear to cause PD.
Alpha-synuclein oligomers ultimately develop into fibrils,
the main constituent of Lewy bodies (6). These protein aggre-
gates are considered a hallmark of synucleinopathies, a class
of disorders that affects various brain regions, including the
cerebral cortex and the substantia nigra pars compacta.
Alpha-synuclein is expressed in neural cell soma during
development from week 11, but the protein is then redistribu-
ted to the nerve terminals within the adult brain (7–9).
Although a role for a-synuclein has been proposed in synaptic
transmission (10), its function remains unclear and might vary
with its intracellular localization and the stage of neuronal
maturation.
Over-expression of both wild type and mutated forms of
a-synuclein has been used to develop genetic models of the
disease in yeast (11), Caenorhabditis elegans (12), Drosophila
(13), mice (14–16), rats (17,18) and primates (19). While of
great interest, these models often fail to reproduce cardinal
features of the disease. For example, the loss of nigral dopa-
# The Author 2007. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournals.org
*correspondence should be addressed. Tel: þ1 6082658668; Fax: þ1 6082635267; Email: svendsen@waisman.wisc.edu
Human Molecular Genetics, 2007, Vol. 16, No. 6 651–666
doi:10.1093/hmg/ddm008
Advance Access published on February 19, 2007
minergic neurons is rarely observed in a-synuclein transgenic
mice (14,15). Although a-synuclein over-expression in invert-
ebrates leads to remarkable phenotypes, the absence of any
endogenous a-synuclein homolog constitutes a caveat in
these models. Clearly, there is a need to complement animal
models with in vitro human systems to elucidate the specifici-
ties of the human condition (20).
Recently, culture systems have been defined to expand stem
and progenitor cells from human embryonic tissues. These
cells provide both a unique window on human development
and a renewable source of non-transformed neural cells.
Human neural progenitors derived from the fetal cortex
(hNPCctx) mostly differentiate into small bipolar interneurons
and follow a time-dependent transition from neuronal to glial
fate that mimics human cortical development during their 30–
50 week expansion in vitro (21,22). Human embryonic stem
cells (hESC) derived from the inner cell mass of the blastocyst
(23), can be efficiently differentiated into neuroepithelial cells
that produce subsets of long-projection neurons, such as moto-
neurons (24) and dopaminergic neurons (25,26) upon exposure
to specific morphogens. These neurons formed in vitro present
morphological, biochemical and physiological properties
similar to their in vivo counterparts, although their functional
properties remain to be tested.
Both of these cell sources offer great promise to develop
human genetic models of neurodegeneration. In the present
study, we have developed a system of lentiviral infection to
determine the effects of a-synuclein over-expression on the
fate and survival of both neural progenitors and differentiating
neuronal populations.
RESULTS
Human NPCctx express truncated and oligomeric forms of
a-synuclein
We first confirmed that a-synuclein mRNA was present in
wild-type hNPCctx by real-time PCR (data not shown) and
determined what form of a-synuclein was present in native
hNPCctx and how this compared to those over-expressing
a-synuclein. In protein extracts of cells over-expressing
a-synuclein, the LB509 antibody (epitope: amino acids
115–122) recognized a 16 kD band corresponding to the full
length protein but failed to recognize any protein in native
hNPCctx (Fig. 1). As C-terminal a-synuclein truncations
have been described in human cell and brain extracts (27),
we used two antibodies recognizing a more N-terminal
portion of the protein: the polyclonal antibody AB5038
(epitope: amino acids 111–131) and the monoclonal antibody
Syn204 (epitope: amino acids 102–110). While these two
antibodies recognized the over-expressed full-length form,
they also detected a shorter form of a-synuclein, present in
both native hNPCctx and over-expressers (Fig. 1). To detect
full-length forms of a-synuclein, we enriched cytosolic
protein extracts of hNPCctx by immunoprecipitation using
the monoclonal antibody Syn211 (epitope: amino acids
120–125) and used the LB509 antibody for immunodetection.
In addition to the over-expressed full-length monomer in aSyn
WT hNPCctx, high molecular weight species migrating as a
36 kD doublet () and 30 kD band () could be detected in
protein extracts of both native and infected cortical progeni-
tors (Supplementary Material, Fig. S1A). In the absence of
immunoprecipitation, the LB509 antibody weakly recognized
a similar 36 kD doublet in nuclear protein extracts of non-
infected hNPCctx (Supplementary Material, Fig. S1B). These
bands might correspond to either ubiquitinated or oligomeric
forms of a-synuclein (28).
Together, these results show that a-synuclein is expressed
at low levels in cultured native progenitors of the human
cortex. The protein seems to undergo extensive post-
translational modifications, such as truncation and oligomeri-
zation. When over-expressed using lentiviral vectors, the
16 kD full-length form accumulates in hNPCctx.
Establishment of transgenic hNPCctx populations
over-expressing a-synuclein and its mutants:
mutation-dependent expression levels
We next sought to establish transgenic populations of hNPCctx
to determine the effect of a-synuclein over-expression on
hNPCctx phenotype. Human neural progenitors were derived
from the fetal cortex (age 87–94 days, donors M006, M031,
M045 and M046) and grown as neurospheres for more than
30 weeks in vitro. During that time, they progressively
switch from an essentially neurogenic fate to a mainly glio-
genic fate. At 10–20 weeks of expansion, transiently disso-
ciated neurospheres were infected by exposure to lentiviral
vectors coding for a-synuclein WT (aSyn WT), A30P or
A53T (Fig. 2A). The progenitors then reformed spheres that
could be expanded in the presence of EGF/LIF and compared
with either non-infected or GFP-infected hNPCctx.
Four days following infection, we could detect over-
expression of GFP (Fig. 2B) and a-synuclein (Fig. 2C,
immunocytochemistry with the LB509 antibody) in hNPCctx.
The wild type and A53T forms displayed both a nuclear and
a punctate cytoplasmic staining while the A30P form appeared
more homogenously distributed. At this early stage, transgene
over-expression could be detected in .75% of the cells in
every condition. After 1 month of expansion, the number of
integrated transgene genomic copies was assessed in
hNPCctx derived from three independent donors (M031,
M045 and M046). Five infections of hNPCctx populations
led to similar relative numbers of transgene copies for each
lentivirus based on qPCR (Fig. 2D), within a range of 5–10
integrated copies/cell. This confirmed the comparable effi-
ciency of each of the four lentivirus preparations.
Figure 1. Alpha-synuclein expression in hNPCctx. Western blot analysis of
a-synuclein expression in hNPCctx either uninfected or infected with a lenti-
virus for aSynWT over-expression. Three antibodies were used: LB509,
AB5038 and Syn204.
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Relative amounts of WPRE mRNA expressed per gene
copy were then determined for each infected population of
hNPCctx. When compared with aSyn WT, divergent levels
of expression were obtained for the two mutants (Fig. 2E).
In four independent infections (M031 and M046 donors) per-
formed before passage 15, A53T expression was significantly
decreased when compared with the two other forms (260%).
In four infections performed after passage 15 in culture, we
Figure 2. Quantification of transgene integration and expression following lentivirus infection. (A) Schema of the hNPCctx culture system: transgenic popu-
lations were obtained by lentiviral infection of dissociated neurospheres. Over time in culture, the fate of hNPCctx evolves from neuronal toward glial cell pro-
duction. (B) GFP expression in transgenic and non-infected populations of hNPCctx. Scale bar 40 mm. (C) Immunocytochemistry of a-synuclein expression in
hNPCctx (LB509). Note the low level of expression in the non-infected cells and the diffuse distribution of the A30P mutant. Scale bar 10 mm. (D) Relative
quantification of integrated transgene copy numbers (WPRE normalized with respect to albumin) in five transgenic populations of hNPCctx (E) Box-and-Whisker
plot showing the transgene expression levels of a-synuclein mutants per transgene copy (WPRE expression normalized with respect to b-actin). Mutants are
compared with aSynWT (arbitrarily set at 1) in four populations of hNPCctx, infected either before passage 15 or after passage 15. Note the relatively low
level of expression of the A53T form and the increase in A30P expression as a function of the time of infection. (F) Representative western blot and quanti-
fication of protein expression per gene copy in three populations of hNPCctx over-expressing a-synuclein and its mutants (LB509 antibody, a-synuclein normal-
ized with respect to a-actin).
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noticed a higher expression level of the A30P mutant when
compared with aSyn WT (M031, M045 and M046 donors,
þ36%). The A53T form was again expressed at relatively
low levels (259%).
To confirm a similar effect on protein expression, we
assessed a-synuclein levels by western blotting (LB509 anti-
body, Fig. 2F). Endogenous 16 kD a-synuclein is not detected
in these conditions (see Fig. 1). In over-expressers, the LB509
antibody recognizes specifically a 16 kD band, with a 35 kD
oligomeric form detectable in cells over-expressing the
A53T mutant. Semi-quantitative determination of a-synuclein
expression per transgene copy in hNPCctx infected after
passage 15 (M031, M045 and M046 donors), revealed the
same divergence in protein expression levels: 44% increase
of the A30P form and an 80% decrease for the A53T form,
when compared with aSyn WT.
These data show that hNPCctx tightly regulate their level of
a-synuclein over-expression following lentiviral transduction,
as a function of both time of infection and pathogenic
mutation. This observation suggests adaptive effects in the
Figure 3. Analysis of progenitor fate and survival in response to a-synuclein over-expression. (A) TUNEL staining and a-synuclein immunocytochemistry on
hNPCctx 4 days after lentiviral infection. Arrowheads indicate TUNELþ cells. Scale bar 40 mm. (B) Quantification of TUNELþ cells in four populations of
hNPCctx derived from four independent donors, 4 days post-infection (P, 0.01 versus GFP, P, 0.001 versus aSynWT and A30P). (C) Immunocytochemistry
for GFAP (red) and TuJ1 (green) on hNPCctx (passage 31) differentiated for 7 days. Scale bar 100 mm (D) Quantification of M031 neurosphere differentiation
over time in culture, expressed as the ratio of GFAPþ cells with an astrocytic morphology over TuJ1þ neuronal cells. Progenitors over-expressing aSyn WT are
compared with control cultures (non-infected and GFP-infected). Data are expressed as mean + SD, n ¼ 3 for each condition. (E) Percentage of GFAPþ pro-
duced after 7 days of differentiation at passage 20, 26 and 31 in the M031 hNPCctx.  P, 0.05,  P, 0.001; n¼3 for each condition. (F) Differentiation (7 days)
and survival, expressed as a percentage of TUNELþ cells, in dissociated cultures of M031 hNPCctx at passage 29.  P, 0.05, n ¼ 3.
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hNPCctx populations that, in the case of the A53T mutation,
eliminate cells with high transgene expression levels. This
result prompted us to assess carefully how hNPCctx respond
to a-synuclein over time in culture.
Over-expression of the A53T a-synuclein mutant induces
acute cell death in hNPCctx
The lower level of a-synuclein expression in the A53T
hNPCctx might indicate a cytotoxic effect leading to the loss
of high expressers. To determine if that was indeed the case,
hNPCctx derived from the M006, M031, M045 and M046
donors were infected in parallel with the GFP, aSyn WT,
A30P and A53T lentiviruses. Four days after infection,
a-synuclein cytotoxicity was analyzed by TUNEL (Fig. 3A
and B). Percentage of TUNELþ cells following aSyn WT
and A30P infections was 9.0+ 1.1 and 10.0+ 1.5, respect-
ively, a value similar to the GFP infection (11.4+ 1.5%).
An identical titer of the A53T lentivirus induced significantly
higher cell death, with 16.4+ 2.2% of TUNELþ cells
averaged over the four independent populations of hNPCctx
(P , 0.01 versus GFP, P , 0.001 versus aSyn WT and
A30P, repeated measures ANOVA).
Thus, over-expression of the A53T mutant induces acute
toxic effects in hNPCctx that prevent the establishment of
expression levels comparable to the two other a-synuclein
forms. For this reason, further analysis of the a-synuclein
effects in hNPCctx lines was focused on the aSyn WT and
A30P variants.
Induced over-expression of aSyn WT prevents the
progressive switch of hNPCctx to glial cell production
We next explored whether a-synuclein over-expression in
hNPCctx affected their ability to differentiate into neurons
(TuJ1þ) and astrocytes (GFAPþ, astrocytic morphology).
Expanded neurospheres were induced to differentiate for 7
days and their progeny analyzed for TuJ1 and GFAP (donor
M031, Fig. 3C and D). At 7 weeks post-infection (passage
20), hNPCctx generated 67% TuJ1þ neurons and 24%
GFAPþ astrocytes (ratio GFAPþ/TuJ1þ ¼ 0.35–0.37) in
non-infected, GFP and aSyn WT populations. As expected,
the proportion of neurons produced upon differentiation
decreased progressively over time, in both uninfected and
GFP hNPCctx, leading to the production of a majority of
GFAPþ cells with an astrocytic morphology at passage 31
(ratio of GFAPþ/TuJ1þ ¼ 1.30–1.33) (Fig. 3D and E). Inter-
estingly, hNPCctx over-expressing aSyn WT showed a signifi-
cant reduction in the number of astrocytes versus neurons
produced at passage 26 and 31 (Fig. 3D and E). At passage
31, the ratio GFAPþ/TuJ1þ was only 0.75+ 0.02 (SD) in
the differentiated aSyn WT hNPCctx; P , 0.001 when com-
pared with controls. A similar lack of gliogenesis was
observed in hNPCctx derived from the M046 donor (data not
shown).
A30P a-synuclein also impaired the production of GFAPþ
glial cells in M031 hNPCctx at passage 31, when compared
with the non-infected and GFP progenitors (Fig. 3E). Never-
theless, A30P hNPCctx consistently produced more GFAPþ
cells than the aSyn WT over-expressers, both at passages 26
and 31 (P , 0.001). This suggests a pro-gliogenic effect of
the A30P mutation when compared with aSyn WT. Again,
hNPCctx derived from the M046 donor showed a similar
pattern (data not shown).
To analyze whether a-synuclein induced selective cell
death during differentiation, M031 hNPCctx were dissociated
at passage 29 and induced to differentiate for 7 days. We
then determined both the ratio of GFAPþ/TuJ1þ cells and
percentage of TUNELþ cells. As expected, aSyn WT over-
expression led to a significant reduction in the ratio
GFAPþ/TuJ1þ (1.08+ 0.02 for aSyn WT versus
1.45+ 0.09 and 1.56+ 0.11 for the non-infected and GFP
controls, standard error of the mean (SEM), P , 0.05)
(Fig. 3F). We did not observe any significant difference in
the percentage of TUNELþ cells, showing that the effect of
a-synuclein on the fate of cortical progenitors was not
mediated by selective cell death in their progeny. Together,
these data suggest that a-synuclein over-expression prevents
the progressive switch of hNPCctx toward glial cell production,
an effect that does not depend on cell death.
When over-expressed, a-synuclein affects the proliferation
of gliogenic precursors and localizes both in the cell
nucleus and around cytoplasmic microvesicles
We next sought to determine whether a-synuclein might affect
the proliferation of hNPCctx, preventing the establishment of
normal astrogliogenesis. As the mixed fate of hNPCctx can
confound the analysis of progenitor proliferation, we modified
the culture conditions to establish a population of progenitors
with mostly a glial fate. Neurosphere cultures were first grown
for 28–30 passages in response to EGF alone until they
stopped proliferating. At that time, LIF was added in the
culture medium, stimulating for 6 additional weeks the
growth of hNPCctx with a mostly glial fate (.75% GFAPþ
cells after 7 days of differentiation).
In these conditions, we measured the proliferation rate of
hNPCctx derived from the M046 donor at passage 31 by deter-
mining nuclear Ki67 immunoreactivity (Fig. 4A and B). We
observed a significant decrease in the percentage of Ki67þ
nuclei in response to aSyn WT (17.1+ 0.8% versus
23.4+ 1.7% (non-infected) and 21.7+ 1.3% (GFP), SEM,
P , 0.05). Progenitors expressing the A30P mutant had a pro-
liferation rate significantly higher than the aSyn WT over-
expressers, with 21.0+ 1.2% of Ki67 þ nuclei (P , 0.05).
A similar effect was observed in the M031 line, when cell pro-
liferation was measured by bromodeoxyuridine (BrdU)
pulsing (Supplementary Material, Fig. S2).
Thus, aSyn WT over-expression decreases the proliferation
rate of gliogenic progenitors. When compared with aSyn WT,
the A30P mutation facilitates glial progenitor proliferation.
This difference in the cell response to these two a-synuclein
forms parallels the observed differences in the relative trans-
gene expression levels (Fig. 2D), with a higher level of
A30P protein in progenitors infected at later, more gliogenic
passages.
In the same culture conditions, immunocytochemistry using
the LB509 antibody revealed a punctate staining of aSyn WT
in the cytoplasm, and a diffuse nuclear distribution (Fig. 4C).
Cells over-expressing A30P showed a more diffuse localiz-
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ation throughout the cell, including the nucleus. We next com-
pared the distribution of over-expressed aSyn WT and A30P
in hNPCctx populations with a predominantly neuronal fate
(passage ,26, ratio GFAPþ/TuJ1þ cells 1) or mainly
glial fate (passage .30, ratio GFAPþ/TuJ1þ cells .3)
(M031, Fig. 4D). At early passages, both wild-type and
A30P a-synucleins were clearly present in the nuclei in
30% of hNPCctx. The nuclear staining appeared diffuse
and was easily distinguishable from the punctate cytoplasmic
staining. In cells with mostly a glial fate (passage 33),
aSyn WT appeared mainly clustered in the cytoplasm
(10.3+ 0.6% nuclear localization, P , 0.001 when compared
to passage 26). With the A30P mutant, a larger proportion of
progenitors displayed nuclear localization (17.3+ 0.7%,
P , 0.01 when compared to aSyn WT). These data were con-
firmed in hNPCctx derived from the M046 donor (data not
shown). Thus, there is a shift in the sub-cellular localization
of a-synuclein over time in culture, correlating with the
Figure 4. Progenitor proliferation and a-synuclein subcellular localization (A) Ki67 immunocytochemistry on M046 hNPCctx. Arrowheads indicate Ki67 þ
nuclei. Scale bar 50 mm (B) Proliferation of gliogenic hNPCctx (M046 donor, passage 31), as determined by the percentage of Ki67þ nuclei. P, 0.05,
n ¼ 3 for each condition. (C) Alpha-synuclein immunocytochemistry in M031 hNPCctx over-expressing aSyn WT and A30P. Note the decrease in aSyn
WT nuclear localization between passage 26 and 33 (mainly gliogenic progenitors) in culture. (D) Quantification shows a significantly higher nuclear localization
of over-expressed a-synuclein carrying the A30P mutation at passage 33. Scale bar 25 mm, P, 0.01 versus A30P, P, 0.001 versus passage 26, P, 0.001
versus passage 26; n ¼ 3 for each condition, two-way ANOVA. (E) Immunogold labeling of a-synuclein and electron microscopy on M046 hNPCctx. Note
a-synuclein presence in the cell nucleus (white arrowheads) and clustering around microvesicles (black arrowheads). In cells over-expressing the A30P
mutant, a-synuclein clusters are rarely observed. Scale bars: 2 mm and 0.5 mm (insets showing microvesicles).
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change in the fate of the progenitors. This re-distribution is
disrupted by the A30P mutation.
Control lines and a-synuclein over-expressers derived from
the M046 donor and grown continuously in EGF and LIF were
immunogold-labelled for a-synuclein (AB5038 antibody) and
analyzed by transmission electron microscopy (TEM)
(Fig. 4E). Alpha-synuclein was detected both in the cytoplasm
and nucleus of all lines, and when over-expressed, frequently
formed clusters around cytoplasmic microvesicles of unknown
function. In contrast to wild-type and A53T a-synuclein, the
A30P mutant protein was rarely observed in clusters, consist-
ent with its reduced affinity for membranes (11,29,30).
Human ES cells: a source of long projection neurons that
can be genetically modified to over-express a-synuclein
We next wanted to establish the effects of a-synuclein in
human dopaminergic neurons derived from stem cells. Due
to regional specification at the time of tissue collection,
expanded progenitors derived from the developing human
brain produce only a limited set of neuronal cell types that
do not include dopaminergic neurons, even when generated
from the mesencephalon (31,32). To address this issue, we
used hESC as a source of neuroectoderm producing long pro-
jection neurons, including dopaminergic neurons (Fig. 5).
Colonies of hESC (H9 line) were differentiated into adherent
neuroepithelial cells in the presence of FGF2. As described
previously, sequential exposure to FGF8 and sonic hedgehog
(SHH) specifies a progenitor population that further matures
into neurons with a set of markers and physiological properties
similar to the ventral midbrain dopaminergic neurons (25,26).
Neuroepithelial cells were positive for nestin, a marker of
neural progenitor cells, and continuously produced cells
expressing neuronal markers such as TuJ1 and Map2ab
(Fig. 6A). Using the GFP lentiviral vector, we obtained high
transduction efficiency of differentiating neuroepithelial pro-
genitors and neurons. GFP expression, detected from day 4
after infection, was still present in .70% of the cells 22
days post-infection and maintained in neuronal cells expres-
sing tyrosine hydroxylase (TH) (Fig. 6B). Using the pre-
viously characterized lentiviral vectors coding for aSyn WT,
A30P and A53T, we could detect transgene over-expression
22 days post-infection (Fig. 6C). It was of interest that non-
infected cells with a neuronal morphology showed a faint
a-synuclein staining in their cytoplasm, suggesting a low
level of endogenous expression.
Over-expression of a-synuclein is cytotoxic to
differentiating cultures of neuroepithelial cells specified
with FGF8 and SHH
Neuroepithelial cells obtained as described in Fig. 5 were
specified with FGF8 and SHH. After 3 days of terminal differ-
entiation, cells were infected with lentiviral vectors (4 ng p24)
coding either for GFP, aSyn WT, A30P or A53T. Four days
Figure 5. Schema of the hESC differentiation protocol. Human ESC are differentiated following a stepwise protocol in chemically defined conditions. Initial
differentiation is induced by the formation of embryoid bodies, followed by neural induction in the presence of FGF2. For neural specification, adherent colonies
are exposed to FGF8 for rostro-caudal specification. Neurosphere cultures are further patterned with SHH (dorso-ventral specification). Dissociated cultures of
neuroepithelial are exposed to lentiviral vectors for a-synuclein over-expression during the terminal step of differentiation.
Figure 6. Terminal differentiation of neuroepithelial cells. (A) Nestin (red)
and Map2ab (green) immunocytochemistry on neuroepithelial cells derived
from the H9 hESC line on day 10 of terminal differentiation. Scale bar
100 mm. (B) GFP expression in differentiating cultures of neuroepithelial
cells (day 22 of terminal differentiation, 21 days post-infection). Immunocyto-
chemistry for TH (red) demonstrates the presence of dopaminergic neurons
over-expressing GFP. Scale bar 50 mm. (C) Alpha-synuclein expression
(LB509 antibody, red) in differentiating neuronal cultures derived from
hESC. Arrowheads indicate THþ cells (green) staining positively for
a-synuclein. Note the presence of a low level of endogenous a-synuclein
(non-infected neurons) and the detectable over-expression at day 22 of term-
inal differentiation (21 days post-infection). Scale bar 50 mm.
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post-infection, we analyzed cell death by TUNEL staining
(Fig. 7A). Infection with the GFP vector had no detectable
toxicity in these conditions, with 19.2+ 4.6% TUNELþ
nuclei versus 19.9+ 1.5% in the absence of infection
(Fig. 7B). All three a-synuclein forms induced cell death,
with 41.2+ 4.5% (aSyn WT), 46.8+ 5.6% (A30P) and
53.6+ 3.9% (A53T) of TUNELþ nuclei detected for each
condition (Fig. 7B). Expression of TH could be seen in a
subset of cells, indicating that terminal differentiation of dopa-
minergic neurons was underway (data not shown). About 30%
of total cells expressed neuronal markers such as TuJ1 and
Map2ab (Fig. 6A). Thus, a-synuclein over-expression could
be achieved in these cultures, but clearly induced acute tox-
icity to these differentiating neural progenitor cells.
Dopamine synthesis and FGF8/SHH specification of
neuronal cultures contribute to acute toxicity in response
to a-synuclein over-expression
We next sought to determine what factors specifically render
these neuronal cell cultures sensitive to a-synuclein toxicity.
As dopamine has been proposed to mediate a-synuclein tox-
icity (33), we tested whether a-methyl-p-tyrosine (aMT), an
inhibitor of dopamine synthesis, would reduce the observed
cytotoxicity. Without treatment, we obtained a similar
response to a-synuclein over-expression, with 33.5+ 0.9%
(aSyn WT), 34.2+ 1.3% (A30P) and 37.0+ 0.6% (A53T)
of TUNELþ cells 4 days post-infection (4 ng p24). All of
these conditions resulted in significantly higher amounts of
cell death than seen in the non-infected (12.2+ 0.9%) and
GFP (15.9+ 1.1%) controls (Fig. 8A). Treatment with aMT
had no effect on the non-infected and GFP controls.
However, the cytotoxic effects of a-synuclein over-expression
were significantly decreased, with 25.1+ 1.7% (aSyn WT),
21.1+ 1.6% (A30P) and 20.7+ 1.0% (A53T) of TUNELþ
cells, confirming a role for dopamine in a-synuclein
cytotoxicity.
We next examined whether cell vulnerability to a-synuclein
toxic effects depend on neuroectoderm specification using
FGF8 and SHH, two morphogens involved in the development
of the ventral midbrain. Parallel neuronal cell populations
were derived from the same hESC preparation, specified in
response to either FGF8 and SHH, or FGF2 only (day 8–14
and 20–25 of differentiation). FGF2 specification produced
a neuronal population very similar, in number and mor-
phology, to FGF8/SHH. However, there was a significant
reduction in the number of THþ neurons obtained, with
29.2+ 1.0% (FGF8/SHH) versus 19.9+ 1.1% (FGF2 only)
after 9 days of differentiation (n ¼ 3, P , 0.01).
FGF2-specified cultures were terminally differentiated for 5
days and infected as described previously (4 ng p24). Four
days after infection, we observed again a significantly higher
toxicity in a-synuclein over-expressers, with 16.4+ 0.5%
(aSyn WT), 18.1+ 1.7% (A30P) and 15.7+ 1.5% (A53T)
TUNELþ cells, when compared with the non-infected
(8.7+ 1.1%) and GFP (10.9+ 0.6%) controls. Nevertheless,
with respect to the parallel FGF8/SHH cultures described
earlier, there was a clear decrease in cytotoxicity (Fig. 8B),
suggesting an effect of culture specification on neuronal
vulnerability.
Both in the presence of aMT and following FGF2 specifica-
tion, infection with the GFP lentiviral vector induced a detect-
able expression in most of the neuroepithelial/neuronal cells,
confirming that culture conditions had no major effect on
infection efficacy (Fig. 8C).
These results suggest that dopamine production and/or spe-
cification toward susceptible human brain regions, such as the
ventral midbrain, exacerbate a-synuclein cytotoxicity.
Over-expression of a-synucleins progressively impairs the
neuronal pattern of terminal differentiation
We next analyzed the effects of a-synuclein on the develop-
ment of dopaminergic and GABAergic markers in long-term
(3 weeks) differentiating cultures (26). Neuroepithelial cells
specified with FGF8/SHH were infected with lentiviral
vectors (5 ng p24) after 1 day of differentiation and main-
tained in vitro for 22 days. At 8, 15 and 22 days of differen-
tiation, the cultures were analyzed for the expression of TH
and TuJ1, to determine the percentage of dopaminergic
TuJ1þ neurons. TuJ1 was used as an early indicator of neur-
onal differentiation. The percentage of THþ cells among
TuJ1þ neurons increased steadily from day 8 to day 22, reach-
ing 32.7+ 1.1 and 32.8+ 0.8% in the cells either non-
infected or infected with the GFP control virus, respectively
(Fig. 9A–C). In the a-synuclein over-expressers, the pro-
portion of THþ neurons increased at a significantly lower
rate, which was most pronounced for the A53T mutation
(Fig. 9A–C): 26.0+ 3.2% (aSyn WT), 21.2+ 1.8%
(A30P) and 16.4+ 2.1% (A53T) of THþ /TuJ1þ neurons
at day 22 of differentiation. At this stage, a-synuclein over-
expression could be detected by immunocytochemistry
(Fig. 6C). Thus, in addition to its acute toxic effects,
a-synuclein impairs dopaminergic marker expression in
maturing neuronal cultures derived from hESC.
We next quantified both THþ and GABAþ neurons to
determine whether a-synuclein over-expression had specific
effects on either neuronal phenotype. After 5 days of differen-
tiation, neuronal cultures were infected as described pre-
viously (5 ng p24) and further differentiated for 16 days. It
is noteworthy that this differentiation protocol generates a sub-
population of THþ neurons that also express GABA (25–30%
Figure 7. Cytotoxicity of a-synuclein over-expression in terminally differen-
tiating neuronal cultures derived from hESC. (A) TUNEL staining at day 7 of
differentiation, 4 days post-infection. Scale bar 100 mm. (B) Quantification of
TUNELþ cells. P, 0.01, P , 0.001, n ¼ 4 for each condition.
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of total TH þ neurons), likely with a forebrain positional iden-
tity (olfactory bulb) (26). We analyzed cells for GABA/
Map2abþ and TH/Map2abþ co-expression to determine the
percentage of neurons positive for each of these markers
(Fig. 9D–E). In agreement with the previous experiment,
the proportion of THþ neurons was significantly decreased
(data not shown). In contrast to TH, GABA expression was
mainly affected by aSyn WT over-expression, which resulted
in 51% loss of GABAþ neurons. Interestingly, there was
less effect on GABAþ neurons with the other two mutations
(Fig. 9D; A30P: 30% loss, P , 0.05; A53T: 22% loss,
P , 0.05 versus GFP only). Thus, over-expression of
a-synucleins impairs both the survival and maturation of neur-
onal cells derived from hESC, with dopaminergic and GABA-
ergic markers being differentially affected as a function of
a-synuclein forms.
DISCUSSION
PD, such as other neurodegenerative disorders, affects mainly
the human species. Although neurodegeneration might result
from the prolongation of the human life span, human
neurons are likely to have developed unique features increas-
Figure 8. Inhibition of dopamine synthesis and neuroepithelial cell specification: effect on a-synuclein cytotoxicity. (A) Quantification of TUNELþ cells 4 days
after infection in response to a-synuclein in cells treated with aMT. P , 0.001 versus non-infected, GFP and aMT-treated a-synuclein over-expressers;
P, 0.01 versus aMT-treated non-infected and GFP; n ¼ 3 for each condition. (B) Quantification of TUNELþ cells 4 days after infection in response to
a-synuclein following FGF2 specification. P, 0.001 versus non-infected, GFP and FGF2-specified a-synuclein over-expressers; P, 0.05 versus
FGF2-specified non-infected and GFP; P, 0.05 versus non-treated GFP; n ¼ 3 for each condition. (C) GFP expression 4 days post lentiviral infection and
immunocytochemistry for Map2ab (red). Scale bar 50 mm.
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ing their susceptibility to degeneration (34). We have devel-
oped a system for a-synuclein over-expression in human
embryonic neural progenitors. Over-expression of the A53T
mutant is overtly toxic, while the wild-type form impairs the
normal transition of progenitors from neuronal production
toward glial cell production. In hESC-derived cultures,
which can produce subsets of long-projection neurons that
resemble ventral midbrain dopaminergic neurons, all forms
of a-synuclein induce acute cytotoxicity. This effect depends
both on epigenetic progenitor specification and dopamine syn-
thesis, and impairs the expression pattern of dopaminergic and
GABAergic markers upon terminal differentiation.
Over-expression of a-synuclein in hNPCctx leads to toxicity
and reduced gliogenesis
Alpha-synuclein has been over-expressed in fetal cortical pro-
genitors to monitor its effect on their neurogenic potential. The
wild-type a-synuclein form delays the normal switch to glio-
genesis observed in these cultures. Both the A30P and the
Figure 9. Pattern of differentiating neuronal subtypes. (A) Percentage of THþ neurons over total TuJ1þ neurons, as a function of differentiation time, and in
response to over-expression of a-synuclein and its mutants. (B) The same data at day 22 of differentiation. P, 0.01; P, 0.001; n ¼ 3 for each condition,
two-way ANOVA. (C) Immunocytochemistry for TuJ1 (green) and TH (red) in neuronal cultures derived from hESC and terminally differentiated for 22 days
(21 days post-lentiviral infection). Scale bar 100 mm. (D) Bar graph showing the percentage of GABAþ neurons over total Map2abþ neurons at day 21 of
differentiation. P, 0.01, P, 0.05; n ¼ 3 for each condition. (E) Immunocytochemistry for Map2ab (green) and GABA (red) in hESC-derived neuronal
cultures terminally differentiated for 21 days (16 days post-lentiviral infection). Scale bar 100 mm.
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A53T mutations have specific effects when compared with the
wild-type form: the former enhancing gliogenesis and the
latter inducing acute toxicity. These effects have rather
minor amplitude when compared with the consistent toxicity
observed on terminally differentiated dopaminergic neurons.
Considering the adult onset of autosomal dominant forms of
PD, it is unlikely that the consequence of mutations on pro-
genitors is a primary cause of the pathology. Nevertheless,
the way human cortical progenitor cells respond to these
pathogenic molecules might be a good indicator of pathogenic
events occurring in post-mitotic neurons and glia.
From an evolutionary standpoint, the a-Synuclein gene pre-
sents a remarkable adaptation. In most vertebrates, a threonine
is present at the position 53. However, in Old World monkeys
and humans, position 53 of the a-Synuclein gene encodes an
alanine (35). Back mutation to a threonine in the human
protein induces an early-onset dominant form of PD—the
A53T mutation (2). Why rodents and other vertebrates can tol-
erate this mutation is not known. The acute cytotoxicity of the
A53T mutant using hNPCctx and other studies using human
cells (33,36) demonstrate that species specificities could
have increased the vulnerability of the human brain to this
mutation. All hNPCctx cultures infected with the A53T
mutant show limited transgene expression levels when com-
pared with the wild-type form, suggesting a lower tolerance
threshold of progenitors to a-synuclein A53T.
Studies in over-expressing and knock-out mice proposed a
role for a-synuclein at nerve terminals in the formation/main-
tenance of synaptic vesicles (10,37). But this protein has other
functions yet to be explored. For example, a-synuclein is
expressed during development in the mouse (38), rat (39)
and human brain (7–9). While knock-out mice and over-
expressers do not reveal any developmental defects, this
may in part be related to the species differences discussed
above.
The possible role for a-synuclein in the transition from
human progenitors to mature neurons has not yet been
explored. While a-synuclein is almost exclusively present in
nerve terminals during adulthood, it has been found in the
perikarya during development (8,9). This change in subcellu-
lar localization indicates that a-synuclein function may evolve
as neural differentiation and maturation progresses. We show
here that hNPCctx express a-synuclein, although at a low level.
When over-expressed, the protein accumulates both at cyto-
plasmic microvesicles and in the cell nucleus. This nuclear
localization is reminiscent of initial studies that discovered
the protein in neurons of the Torpedo electric organ, both at
synaptic terminals and in the nucleus (‘syn-nuclein’) (40).
Alpha-synuclein has been found associated with histone pro-
teins (41) and affects both their acetylation and expression
levels (41–44). With normal aging, a-synuclein accumulates
in the cell soma (45), and forms Lewy bodies in diseased
brain. Clustering around microvesicles might represent an
early step leading to the formation of these inclusions,
which contain both lipids and proteins (46). Aberrant
a-synuclein localization in adult neurons might be due to elev-
ated expression and may improperly re-activate a cell response
normally driving the transition from progenitors to immature
neurons. Whether this is part of the disease process will
require further investigation.
When induced to differentiate, early passage hNPCctx that
constitutively over-express a-synuclein produce neurons at a
normal rate. However, the reduced production of astrocytic
cells at later passages suggests that a-synuclein impairs the
normal transition to gliogenesis. Factors inducing the switch
to glial cell production are still poorly understood. EGFR
level controls the timing of astrogliogenesis (47), triggered
by an autoregulatory activation of the JAK-STAT signaling
pathway (48). How a-synuclein maintains hNPCctx in their
neurogenic stage remains unclear. Nevertheless, its intracellu-
lar distribution changes over time, cytoplasmic accumulation
coinciding with impaired gliogenesis (Fig. 5B). Progenitors
expressing the A30P mutant, with a more pronounced
nuclear localization over time, consistently produce more
glial cells than the wild-type form. The effect of a-synuclein
on the neural/glial fate of progenitors may thus depend on
its cellular distribution between the membrane/cytoplasmic/
nuclear compartments. As a-synuclein could function as a
physiological regulator of enzymes, transporters and vesicle
formation, one can speculate a stabilizing effect on pro-
neurogenic signaling pathways at the expense of the pro-
gliogenic ones, thereby decreasing the proliferation rate of
gliogenic progenitors. Possible interactions with the DNA
matrix, as suggested by its association with histone proteins,
might also influence gene transcription pattern and fate of pro-
genitor cells. Important physiological effects on hNPCctx prior
to differentiation into neurons, lends further credence to a
widespread effect of a-synuclein over-expression and not
just at the synapse.
Alpha-synuclein and its mutants induce acute toxicity in
hESC-derived neuronal cultures that is sensitive to
dopamine and neurodevelopmental specification
PD is a progressive disorder that affects multiple neuronal sub-
types. As proposed recently, the disease could initially affect
enteric (49) and cardiac sympathetic innervations, propagate
into the central nervous system via the brainstem and the
olfactory bulb, and spread into the ventral midbrain dopamin-
ergic system, locus cœruleus and cerebral cortex (50).
However, degeneration of long-projection dopaminergic
neurons in the substantia nigra pars compacta remains a pro-
minent feature that leads to some of the most severe
symptoms.
Both mouse and human ES cells can be efficiently differen-
tiated into neuroepithelial cells, further specified into dopa-
minergic long-projection neurons (25,26,51,52). As such,
they provide a flexible source of cells that can be used to
develop in vitro models of PD. Using mouse ES cells, this
approach has already been explored by over-expressing
a-synuclein (53). In both cases, additional exposure to oxi-
dative stress and proteasome inhibition is needed to reveal
increased cell vulnerability. Alpha-synuclein also leads to
neuronal loss in response to prolonged cell culture.
In order to generate cells with selective vulnerability to
a-synuclein, we have used neuroepithelial cells derived from
hESC, and specified using SHH and FGF8. This culture
system is still immature, and does not reproduce all the
connectivity and cell extrinsic factors specific to the adult sub-
stantia nigra. Nevertheless, it provides a source of non-
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transformed human neuronal cells that synthesize dopamine
and have been specified using the factors that govern the
development of the ventral midbrain (54). We have observed
an acute toxicity of a-synuclein per se at low viral doses
with a PGK promoter system driving mid-level expression.
As expected, all three forms of a-synuclein are toxic, includ-
ing the wild-type form, whose additional gene copies induce
dominant PD. Clearly, differentiating human neuronal cultures
are highly vulnerable to a-synuclein without the need for any
additional stress. This susceptibility is linked to specific cellu-
lar conditions, since inhibition of TH, the rate-limiting enzyme
in dopamine synthesis and neurectoderm specification using
FGF2, which shifts the pattern of neuronal subtypes produced,
both reduce cytotoxicity. Alpha-synuclein induces death in
human progenitors developing into long projection neurons,
at a stage where the cells have not established organized
synapses yet, in a large fraction of cells that goes beyond
the population of THþ neurons. It is unclear whether the pro-
gressive decrease in the proportion of THþ and GABAþ
neurons in response to a-synuclein reflects a selective cyto-
toxicity (33,55) or a reduction in the differentiation of neur-
onal sub-types. Interestingly, a-synuclein over-expression
has been shown to directly affect TH expression, suggesting
possible direct effects on the presence of these neuronal
markers (56).
Towards the development of in vitro models of
neurodegeneration in human cells
In vitro models based on human progenitor cells might comp-
lement the genetic animal and cell models recently estab-
lished. Ideally, a human cell model should be based on
mutations with a causative role demonstrated in patients,
and recapitulate pathological features such as protein aggrega-
tion and progressive neuronal dysfunction and/or death. With
the growing number of mutations discovered, genetic models
are now proposed for most neurodegenerative disorders,
including Alzheimer’s disease, PD, Huntington’s disease and
amyotrophic lateral sclerosis. Fetal and embryonic stem cells
could be derived from human samples carrying the mutations
or generated by nuclear transfer from adult donor cells (57).
However, ethical concerns and technical hurdles still limit
the derivation of these cells and it remains unclear whether
culture conditions and exogenous stress will accelerate a
pathogenesis that normally develops over decades. Viral
gene transfer constitutes a flexible system to induce stable
transgene integration in a high percentage of cells, and
control both the time and level of expression. Although this
approach still needs refinement to better recapitulate the pro-
gressive degeneration and the time-dependent protein aggrega-
tion, it paves the way for the design of hESC-based cell
technologies as a tool to dissect neurodegeneration and
screen for therapeutics.
MATERIALS AND METHODS
Lentiviral vector production and titration
Vesicular stomatitis virus G (VSV-G)-pseudotyped lenti-
viruses were produced by transient calcium phosphate cotrans-
fection of 293T cells as described previously (58). Lentiviral
vector concentrations were initially normalized according to
the p24 (HIV-1 capsid protein) content of supernatants
measured by enzyme-linked immunosorbent assay. Ten-times
concentrated stocks of lentiviruses were used for cell
infection.
To obtain a better assessment of the infectious viral par-
ticles, viral genomes were titered using a RT-qPCR protocol
adapted from the method of Lizee et al. (59). Lentiviral
vector particles quantified by ELISA for the p24 viral coat
protein were suspended in PBS at a concentration of
1000 ng p24/ml. Two 10-fold serial dilutions were made in
PBS and RNA was isolated using the RNeasy kit (Qiagen,
Germany) according to the manufacturer’s protocol including
the optional DNase step. Reverse transcription was performed
using random hexamer primers and Superscript III RT (Invi-
trogen, Carlsbad, CA, USA), according to the manufacturer’s
protocol. Taqman assays were performed in triplicate using
2 ml template cDNA, Taqman Universal master mix
(Applied Biosystems, Inc, Foster City, CA, USA), primers
and probe for WPRE (see below). A standard curve was con-
structed using the virus shuttle vector plasmid as template and
used to calculate relative RNA content. Viral p24 titers were
adjusted to reflect the amount of RNA present in each viral
preparation.
Cell culture
Culture of hNPCctx Human fetal cortical progenitor cells
(hNPCctx) were isolated by dissection from post mortem
brain tissue from the following donors: M006, male at 87
days of gestation; M031, male at 94 days of gestation;
M045, male at 91 days of gestation; M046, male, 87 days of
gestation. The methods of collection conform to the National
Institutes of Health guidelines and University of Wisconsin
Institutional Review Board requirements for the collection of
such tissue. Human NPCctx were cultured in 70% DMEM
(high glucose, supplemented with l-glucosamine), 30%
Ham’s F-12, 1% antibiotic-antimycotic, 2% B27 (all from
Invitrogen), 20 ng/ml EGF (Sigma, St Louis, MO, USA),
20 ng/ml FGF2 (R&D Systems, Inc., Minneapolis, MN,
USA) and 5 mg/ml heparin (Sigma) for 4 weeks after which
the FGF2, heparin and B27 were removed and 1% N2 (Invitro-
gen) was added. Neurosphere aggregates were maintained at
200 mm by chopping with a McIlvain tissue chopper (Vibra-
tome, St Louis, MO, USA) when the majority of the spheres
in culture reached a diameter 0.5 mm. Progenitors were
maintained at a density of 5x105 cells/ml of medium, half of
the medium being replaced with fresh medium every 3 days.
Unless stated otherwise, 10 ng/ml leukemia inhibitory factor
(LIF; Chemicon, Temecula, CA, USA) was added to the
media after 10–15 weeks in culture.
Differentiation of hNPCctx For differentiation, spheres were
collected by gravity sedimentation, washed three times with
basal media (no growth factors) and resuspended in plating
media (DMEM/F-12, 2% B27). Whole spheres were adhered
to laminin-coated plastic and allowed to differentiate in
plating media for 7–10 days. During differentiation, half of
the plating medium was replaced every 2 days with fresh
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medium. To facilitate cell immunostaining and counting, the
differentiated cultures were detached by a 5 min Accutase
(Chemicon) treatment, washed to remove enzyme and replated
on glass coverslips coated with poly-L-lysine and laminin.
After a brief incubation for 2–4 h in Neurobasal medium
(Invitrogen) supplemented with 1 mM l-glutamine, 2% B27
and 1% fetal bovine serum (FBS) for cell adhesion, the cul-
tures were fixed in 4% paraformaldehyde for immunocyto-
chemistry. Alternatively, neurospheres were dissociated
10 min with Accutase, washed for enzyme removal and
plated on glass coverslips, at an initial density of 50 000
cells per coverslip. After 7 days of differentiation, the cultures
were fixed for immunostaining and counting.
Infection of hNPCctx Neurospheres were collected 5 days post-
passaging and allowed to settle by gravity. Media was
removed and spheres resuspended in one ml Accutase per 10
million cells, mixed gently and incubated at 378C for
10 min. Accutase was replaced with an equal volume of
0.2% trypsin inhibitor (Sigma) and the cells were washed
three times in 10 ml media. Cells were gently dissociated by
trituration, counted on a hemacytometer and suspended in con-
ditioned media at 1000 cells/ml. 300 000 cells were plated per
well of a 24-well plate (minimum 10 wells) and mixed with
virus diluted to the desired titer in 100 ml of fresh media.
Cells were exposed to a viral concentration of 75 ng p24/ml.
Cells were allowed to re-associate in the presence of virus
and 24–72 h later, small spheres were collected and seeded
into flasks at a density of 500 000 cells/ml. Transgenic
spheres were expanded for 1 month after which molecular
analysis was performed.
Culture of hESC Human ESC (H9 line, NIH registry WA09)
were cultured on a feeder layer of irradiated mouse embryonic
fibroblasts and passaged weekly as described previously (23).
Differentiated colonies were physically removed before
passaging.
Culture, differentiation and infection of neuroectodermal cells
This procedure has been described previously (26). Colonies
of hESC were detached from the feeder layer by a brief
exposure to dispase 1 mg/ml (Invitrogen) and cultured as
cell aggregates in suspension (embryoid bodies) for 4 days
in regular culture medium without FGF2. On day 4, embryoid
bodies were transferred to neural induction medium (DMEM/
F12 1:1 (Invitrogen), 1% N2 supplement, 2 mg/ml heparin and
10 ng/ml FGF2). After 3 days, cells were induced to adhere in
the six-well plates in the presence of 10% FBS and on day 4,
the neural induction medium was supplemented with 50 ng/ml
FGF8 (PeproTech, Rocky Hill, NJ, USA) instead of FGF2,
unless stated otherwise. Ten days after initiation of the differ-
entiation process, colonies started to differentiate into neuro-
ectodermal cells displaying columnar morphology with an
organization into neural tube-like rosettes. Colonies were
grown for 6 days in this medium and then mechanically
detached from the surrounding cells for culture in suspension.
Half of the medium was replaced every other day and once
neurospheres formed, they were mechanically broken using
a Pasteur pipette to facilitate their expansion in small clusters.
Non-neuroectodermal colonies were identified by cell mor-
phology and removed from the culture. After 6–10 days,
40 ng/ml of human SHH (C24II amino terminal peptide,
R&D systems, Inc.) was added to the medium for 5 additional
days. Finally, the neurospheres were carefully dissociated in
Accutase, and 30 000 cells plated on glass coverslips coated
with poly-L-lysine and laminin for terminal differentiation.
The cells were maintained in Neurobasal medium (Invitro-
gen), supplemented with 2% B27, 1% non-essential amino
acids solution (Invitrogen), 1% antibiotic-antimycotic,
0.5 mM l-glutamine, 1 mg/ml laminin, 1 mM cyclic AMP,
200 mM ascorbic acid, 10 ng/ml BDNF (PeproTech) and
10 ng/ml GDNF (R&D Systems, Inc.). Half of the culture
medium was changed every other day. At this stage, the cul-
tures were infected with lentiviral vectors (4–5 ng of p24)
in 300 ml medium (viral concentration ¼ 13–17 ng p24/ml).
Immunocytochemistry and microscopy Cultures were fixed in
4% paraformaldehyde for 20 min at room temperature and
washed in PBS. Fixed cells were blocked in 5% goat or
donkey serum and permeabilized using 0.2% Triton X-100.
Primary antibodies used included monoclonal antibodies
directed against a-synuclein LB509 (1:200; Zymed),
Map2ab (1:250; Sigma), bIII-tubulin (TuJ1, clone
SDL.3D10, 1:3000; Sigma) and rabbit polyclonal antibodies
directed against GFAP (1:1000; DakoCytomation,
Denmark), GABA (1:2000; Sigma), Ki67 (1:1000; NovoCas-
tra, UK), Nestin (AB5922, 1:5000; Chemicon) and TH
(1:500; Pel-Freez, Rogers, AR, USA). Secondary antibodies
used were goat-anti mouse IgG2b AF488 (Molecular Probes,
Invitrogen), donkey anti-rabbit Cy3 (Jackson Immunore-
search, West Grove, PA, USA), donkey anti-mouse Cy3
(Jackson) and goat anti-rabbit AF546 (Molecular Probes).
Nuclei were stained with the Hoechst 33258 dye. Images
were collected using the SPOT Advanced software (Diagnos-
tic Instruments Inc., Burroughs Street, MI, USA) and a SPOT
digital camera mounted on a Nikon microscope E600
equipped with epifluorescence. Cell counts were performed
with the Metamorph imaging software (Universal Imaging,
Downingtown, PA, USA) by an observer blind to the exper-
imental conditions.
Cell proliferation and cell death assays The rate of progenitor
cell division was determined either by Ki67 staining (see
above) or BrdU pulse labeling. Briefly, hNPCctx grown as neu-
rospheres were collected, dissociated with Accutase, replated
at a density of 50 000 cells in 50 ml on a glass coverslip
coated with poly-L-lysine and laminin, and grown in the
regular culture medium supplemented with EGF and LIF.
Three days later, the cells were pulsed with 0.2 mM BrdU
(Sigma) for 14 to 40 h, depending on their growth rate. The
cells were fixed in ice-cold methanol, blocked in 5% donkey
serum and permeabilized with 0.2% Triton X-100. Cells
having incorporated BrdU were immunostained with rat anti-
BrdU antibodies (1:500; Accurate Chemical & Scientific Cor-
poration, Westbury, NY, USA) and goat anti-rat Cy3 second-
ary antibodies (Jackson). Cell fluorescence analysis was
performed as described above and the proliferation rate of
the cells was expressed as the percentage of Ki67þ or
BrdUþ nuclei over the total number of nuclei stained with
Hoechst 33258.
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The rate of cell death in cultures of hNPCctx and differen-
tiated hESC was determined using in situ fluorescent
TUNEL staining (Roche Diagnostics GmbH, Mannheim,
Germany), according to manufacturer’s protocol. Briefly,
cells plated on glass coverslips were fixed in 4% paraformal-
dehyde, blocked and permeabilized as described earlier.
TUNEL labeling was performed for 40 min at 378C and the
cells were subsequently immunostained for a-synuclein or
TH. Cell fluorescence analysis was performed as described
previously and the rate of cell death expressed as the percen-
tage of TUNELþ cells over the total number of nuclei stained
with Hoechst 33258.
Protein analysis Neurospheres were isolated, suspended in 1%
Triton X-100 lysis buffer supplemented with 1% protease
inhibitor cocktail (P8340, Sigma), triturated and centrifuged
at 13 000 rpm for 10 min at 48C. In some experiments,
nuclear and cytoplasmic protein extracts were obtained using
the NE-PER reagents (Pierce, Rockford, IL, USA) following
manufacturer’s protocol. Protein concentration was deter-
mined using the DC protein assay (Biorad, Richmond, VA,
USA). Ten to twenty micrograms of proteins were separated
on 12 or 15% SDS-polyacrylamide gel, and electro-transferred
to nitrocellulose membrane. The membrane was blocked with
5% dry milk in Tris-buffered saline containing 0.1% Tween 20
and probed with primary antibodies toward a-synuclein
(AB5038 rabbit polyclonal, 1:2000, Chemicon; LB509,
1:500, Zymed, San Francisco, CA; Syn204, 1:1000, Lab
Vision, Fremont, CA) and a-actin (monoclonal, 1:1000,
Sigma) and then incubated with either anti-mouse or anti-
rabbit secondary antibodies conjugated to horseradish peroxi-
dase (Promega, Madison). Antibody labeling was visualized
using the ECL chemiluminescence kit (Amersham, Piscat-
away, NJ, USA). For semi-quantitative analysis, signal inten-
sity was analyzed with the Metamorph imaging software
(Universal Imaging) and corrected with respect to the
a-actin loading control.
Immunoprecipitation was performed using sepharose-
protein G beads (Amersham) according to manufacturer’s pro-
tocol. Three micrograms of anti-a-synuclein antibodies
(Syn211, Zymed) were incubated with a neurosphere cell
lysate. After elution, the total protein extract was analyzed
by western blotting using the LB509 antibody as described
previously.
Quantitative PCR Taqman qPCR was performed on an
Opticon 2 (MJ Research, Inc., Waltham, MA, USA) using
Taqman Universal PCR Master mix (Applied Biosystems,
Inc.) and FAM-labeled probes. Genomic DNA was isolated
from neurospheres using DNeasy kit (Qiagen) and 100 ng
per reaction was used as template. RNA was isolated from
neurospheres using RNeasy kit (Qiagen) and reverse transcrip-
tion reactions were performed as described for viral titering,
except that 1 mg of RNA was used for each RT reaction.
One tenth of the total cDNA was used as a template for
qPCR amplification. Standard curves were constructed using
serial dilutions of a plasmid containing WPRE and GDNF
transgene sequences or serial dilutions of genomic DNA for
albumin or cDNA for b-actin. When needed, reaction efficien-
cies were taken into account for quantification of sequence
abundance (WPRE: 1.96; albumin: 2.00; b-actin: 1.99).














Initial sample preparation Fresh cell cultures were fixed on
their glass coverslips in 4% paraformaldehyde, 0.1% glutaral-
dehyde in 0.1M Sorenson’s Sodium Phosphate buffer (PB,
pH ¼ 7.4) for 30 min at room temperature. All antibody and
silver enhancing treatments were carried out on a shaker
table at room temperature, unless stated otherwise.
Antibody treatment Following fixation, the cells were rinsed in
0.1M PB, and treated with freshly prepared 0.1% sodium bor-
ohydride in 0.1M PB for 10 min to quench unbound alde-
hydes. Next, the cells were permeabilized for 30 min with
0.1% Triton X-100 in phosphate buffered saline (PBS,
10 mM Phosphate buffer, 150 mM NaCl, pH ¼ 7.4) followed
by three 10 min rinses in PBS. The cells were then blocked
for non-specific antibody binding with Aurion Goat Blocking
Agent (containing 5% BSA, 0.1% Cold Water Fish Gelatin
and 5% normal goat serum in PBS, pH 7.4; Aurion, The Neth-
erlands) for 30 min. The cells were then rinsed three times for
10 min each in incubation buffer (IB) containing PBSþ 0.1%
BSA-C (Aurion Immuno Gold Reagents). Finally, the samples
were incubated in a mixture of IB and rabbit anti-a-synuclein
at a dilution of 1:500 overnight at 48C. The following day, the
cells were rinsed in IB every 10 min for 2 h (12 rinses total),
then incubated overnight in a 1:100 dilution of Ultra Small
gold conjugate F(ab’) 2 fragment of goat-anti-rabbit IgG
(H&L) (Aurion Immuno Gold Reagents) at 48C. After the
overnight incubation, the cells were rinsed in IB,
6  10 min, and rinsed in PBS 6  5 min. The cells were post-
fixed in 2% glutaraldehyde in 0.1M PB for 30 min, and rinsed
2  5 min in PB.
Silver enhancement The use of Ultra Small gold conjugates
requires a silver-enhancing step to increase the size of the sub-
nanometer gold particles in order to visualize more easily the
particles by TEM. After post fixation, the cells were rinsed
3  10 min in Enhancing Conditioning Buffer (ECS, Aurion
Immuno Gold Reagents). Next the cells were developed in
Silver Enhancement Solution (Aurion Immuno Gold
Reagents) for 1.25 h. To terminate silver enhancement, the
cells were exposed to a solution of 0.3 M sodium thiosulfate
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in ECS for 5 min. The samples were then rinsed 2  10 min in
ECS and finally processed routinely for TEM.
Routine electron microscopy processing After silver enhan-
cing, the cells were fixed in a solution of 1.0% osmium tetrox-
ide in 0.1M PB for 30 min. Following OsO4 post-fixation, the
samples were dehydrated in a graded ethanol series, transi-
tioned in propylene oxide and infiltrated in PolyBed/812
(Polysciences, Inc., Warrington, PA, USA) epoxy resin. The
infiltrated cell populated coverslips were flat-embedded, cell
side up in Al weighing dishes and polymerized for 48 h at
608C.
Ultrathin sectioning After polymerization, the embedded cov-
erslips were removed from the Al dishes. The excess hardened
resin was scraped off the non-cell side, and the glass dissolved
away in Hydrofluoric acid. After extensive distilled water
rinsing, the samples were sectioned for TEM using a Reichert-
Jung Ultracut-E Ultramicrotome, and contrasted with Rey-
nolds lead citrate and 8% uranyl acetate in 50% EtOH. Ultra-
thin sections were observed with a Philips CM120 or a JEOL
100CX electron microscope (80 kV) and images were cap-
tured with a SIS MegaView III (Soft Imaging Systems, Lake-
wood, CO, USA) side-mounted digital camera.
Statistical analysis Unless stated otherwise, data are expressed
as means+ SEM. For quantification of cell death, cell pro-
liferation and immunolabelings, cell counts were performed
on 3 to 4 independent experiments. For each experiment, at
least 1,000 cells total were counted on 5 fields per coverslip.
Data were analyzed using a one- or two-way analysis of var-
iance (ANOVA) followed by a Newman-Keuls post hoc test
on the Prism software (GraphPad Software, Inc., San Diego,
CA, USA). P-values , 0.05 were considered as statistically
significant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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